Imagify, novo contraste de microbolhas, desiste de venda na Europa.

.

In May 2011, Acusphere reached an agreement with the FDA, under a Special Protocol Assessment (SPA), on the design of a placebo controlled trial to demonstrate that stress ultrasound with Imagify has superior efficacy to stress ultrasound without Imagify.

.

http://www.marketwatch.com/story/acusphere-withdraws-its-european-marketing-authorization-application-for-imagify-2014-08-28

.

O novo contraste de microbolhas americano ainda tenta convencer o FDA das vantagens do uso.

Enquanto isso, desistiu de pedir a aprovação na Europa.

.